ES2526171T3 - Adsorbente de fosfato a base de hierro (III)-carbohidratos - Google Patents

Adsorbente de fosfato a base de hierro (III)-carbohidratos Download PDF

Info

Publication number
ES2526171T3
ES2526171T3 ES11152584.6T ES11152584T ES2526171T3 ES 2526171 T3 ES2526171 T3 ES 2526171T3 ES 11152584 T ES11152584 T ES 11152584T ES 2526171 T3 ES2526171 T3 ES 2526171T3
Authority
ES
Spain
Prior art keywords
iii
iron
adsorbent
phosphate adsorbent
phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11152584.6T
Other languages
English (en)
Inventor
Michael Ambühl
Corine Gessier-Vial
Christa Hartmann
Daniel Kaufmann
Ernst Küsters
Ulrich Meier
Andreas Meyer
Nabila Sekkat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38983614&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2526171(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06126122A external-priority patent/EP1932807A1/en
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2526171T3 publication Critical patent/ES2526171T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/06—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group B01J20/04
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • B01J20/223—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material containing metals, e.g. organo-metallic compounds, coordination complexes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
    • B01J20/2803—Sorbents comprising a binder, e.g. for forming aggregated, agglomerated or granulated products
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G49/00—Compounds of iron
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G49/00—Compounds of iron
    • C01G49/0018—Mixed oxides or hydroxides
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G49/00—Compounds of iron
    • C01G49/02—Oxides; Hydroxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • External Artificial Organs (AREA)

Abstract

Un adsorbente de fosfato a base de hierro (III) que incluye i) un material base adsorbente que es almidón ii) óxido e hidróxido polinuclear de hierro (III), y iii) sacarosa, donde dicha sacarosa está incorporada parcialmente en el óxido e hidróxido polinuclear de hierro (III), e incluye además un carbonato, caracterizado por una capacidad para ligar fosfato de por lo menos aproximadamente 140 mg de fosfato adsorbido por 1g de adsorbente de fosfato, y caracterizado porque dicho adsorbente de fosfato a base de hierro (III) es aislado mediante secado por atomización en lecho fluido.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
E11152584
12-12-2014
Como se describe arriba pero con la adición de aproximadamente 3% de hidroxipropil metilcelulosa-HPMC-3 cps, grado 2910 en la fase interior, donde el agente ligante es añadido en el estado seco o parcial o enteramente disuelto en el líquido de granulación; la cantidad de agente ligante es compensada por la cantidad de agente de relleno en el granulado. Los pasos subsiguientes son como se describió en el ejemplo arriba.
5 Ejemplo 14: Gel
(Gel plano acuoso) se calientan 80 mL de agua hasta aproximadamente 70°-75°C. Se añaden 20 g del producto preparado como en el Ejemplo 2 y se mantiene la suspensión a 70°C hasta que se está formando una masa gelatinosa. El gel es mantenido a 70°C por algunos minutos para estabilizar el proceso de formación de gel. Después de enfriar a temperatura ambiente, se añade agua para compensar potenciales pérdidas de agua
10 evaporada durante la manufactura.
Ejemplo 15: Gel
Se disuelven 1.5 mg/mL de benzoato de sodio en agua purificada, se añade 0.2 mg/mL de sacarina de sodio, 1.0 mg/mL de esencia de fresa y el sistema tampón de citrato. Después de completar la disolución, se añade 5 mg/mL de polisorbato 20, entonces se dispersa el adsorbente de fosfato bajo mezcla. Se forma una suspensión
15 homogénea. Finalmente se añade lentamente bajo mezcla 30 mg/mL de hidroxipropilmetil celulosa.
Ejemplos 16-20:
Se disuelven o suspenden los siguientes ingredientes (en mg) en glicerol, se mezclan mutuamente y se empacan dentro de paquetes de barras.
Ej. 16
Ej. 17 Ej. 18 Ej. 19 Ej. 20
Adsorbente de fosfato de ejemplo 2
800 800 800 800 800
HPMC
50 / 50 50 50
Goma arábiga
50 / 50 50 50
Palatone
20 / 20 20 20
Simeticona
20 / 20 20 20
Dióxido de silicio
/ 50 / / /
Hidroxil etil celulosa
/ 100 / / /
Ciclamato de sodio
5 5 5 5 5
4-hidroxibenzoato de metilo
10 10 10 10 10
4-hidroxibenzoato de propilo
5 5 5 5 5
Sabor caramelo
1 1 1 1 1
Etanol
Hasta 10 ml Hasta 10 ml
Propilenglicol
Hasta 10 ml
Glicerol
Hasta 10 ml
Aceite de maíz
Hasta 10 ml
20 Ejemplos 21-22: oblea de dispersión oral
23
imagen22

Claims (1)

  1. imagen1
    imagen2
ES11152584.6T 2006-12-14 2007-12-05 Adsorbente de fosfato a base de hierro (III)-carbohidratos Active ES2526171T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06126122A EP1932807A1 (en) 2006-12-14 2006-12-14 Inorganic compounds
EP06126122 2006-12-14
EP06126101 2006-12-14
EP06126101 2006-12-14

Publications (1)

Publication Number Publication Date
ES2526171T3 true ES2526171T3 (es) 2015-01-07

Family

ID=38983614

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11152584.6T Active ES2526171T3 (es) 2006-12-14 2007-12-05 Adsorbente de fosfato a base de hierro (III)-carbohidratos

Country Status (24)

Country Link
US (2) US8252310B2 (es)
JP (1) JP5456969B2 (es)
KR (1) KR20090094820A (es)
AR (1) AR064301A1 (es)
AU (1) AU2007331482B2 (es)
BR (1) BRPI0720272A2 (es)
CA (1) CA2671828C (es)
CL (1) CL2007003606A1 (es)
EC (1) ECSP099410A (es)
ES (1) ES2526171T3 (es)
HK (1) HK1133248A1 (es)
IL (1) IL198548A0 (es)
MA (1) MA30993B1 (es)
MX (1) MX2009006307A (es)
MY (1) MY151047A (es)
NO (1) NO342285B1 (es)
NZ (1) NZ576672A (es)
PE (1) PE20081381A1 (es)
PT (1) PT2319804E (es)
RU (1) RU2447933C2 (es)
SI (1) SI2319804T1 (es)
TN (1) TN2009000214A1 (es)
TW (1) TWI465239B (es)
WO (1) WO2008071747A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
TWI468167B (zh) 2007-11-16 2015-01-11 威佛（國際）股份有限公司 藥學組成物
JP2009292119A (ja) 2008-06-09 2009-12-17 Alps Electric Co Ltd サーマルヘッド
EP2300153A2 (en) * 2008-06-13 2011-03-30 Novartis AG Manufacture process for the preparation of an iron containing phosphate adsorbent
GB0814326D0 (en) * 2008-08-05 2008-09-10 Medical Res Council Phosphate binding materials and their uses
MX2012000892A (es) * 2009-07-21 2012-06-01 Keryx Biopharmaceuticals Inc Formas de dosificacion de citrato ferrico.
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
DE102011112898A1 (de) 2011-09-08 2013-03-14 Charité - Universitätsmedizin Berlin Nanopartikuläres Phosphatadsorbens basierend auf Maghämit oder Maghämit/Magnetit, dessen Herstellung und Verwendungen
CN103946019B (zh) * 2011-10-13 2016-10-05 维达西姆公司 铁-纤维组合物、其制备和用途
RU2496722C1 (ru) * 2012-04-10 2013-10-27 Леонид Асхатович Мазитов Способ очистки сточной воды от фосфатов
CA2901018C (en) 2013-03-08 2022-05-03 Vidasym, Inc. Metal ion-functional fiber component complex compositions, preparation and uses thereof
US9339489B2 (en) * 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
CA2906029C (en) * 2013-03-15 2017-09-05 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
RS60894B1 (sr) * 2013-11-27 2020-11-30 Vifor Int Ag Farmaceutska kompozicija, koja sadrži čestice vezivnog sredstva za fosfat
US10172882B2 (en) 2014-06-22 2019-01-08 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
US9901918B2 (en) * 2015-03-04 2018-02-27 Graver Technologies Llc Hybrid ion exchange material and method for making the same
CN105193844A (zh) * 2015-05-27 2015-12-30 合肥川迪医药技术有限公司 用于制备含δ-羟基氧化铁(多核)及其药物组合物的方法及在高磷血症领域中的应用
WO2017172633A1 (en) * 2016-03-28 2017-10-05 New Sky Energy Intellectual Property Holding Company, Llc Methods of producing ferrihydrite nanoparticle slurries, and systems and products employing the same
EP3829761A1 (en) 2018-07-30 2021-06-09 Interquim S.A. Process for preparing an adsorbent for phosphate in aqueous medium
EP4090318B1 (en) * 2020-01-16 2024-02-28 Vifor Fresenius Medical Care Renal Pharma, Ltd. Particles of a mixture of iron(iii)-oxyhydroxide, sucrose and one or more starches, preferably of sucroferric oxyhydroxide
CN115317494B (zh) * 2022-07-22 2024-02-13 康瑞鑫(天津)药物研究院有限公司 高磷酸盐结合力的蔗糖氢氧化氧铁及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2885393A (en) 1956-02-24 1959-05-05 R K Laros Company Dextran-iron complex and process for making same
US3697502A (en) 1969-11-03 1972-10-10 Christensen Henry M Method of making iron dextran-preparations
US3951821A (en) * 1972-07-14 1976-04-20 The Dow Chemical Company Disintegrating agent for tablets
US4180567A (en) 1977-09-02 1979-12-25 Pharmachem Corporation Iron preparations and methods of making and administering the same
DE3026868C2 (de) 1980-07-16 1986-03-13 Laboratorien Hausmann AG, St. Gallen Verfahren zur Herstellung von Eisen(III)hydroxid-Dextran-Komplexen und sie enthaltende pharmazeutische sterile wäßrige Lösung
US4569836A (en) 1981-08-27 1986-02-11 Gordon Robert T Cancer treatment by intracellular hyperthermia
EP0330801A1 (en) 1983-02-08 1989-09-06 Schering Aktiengesellschaft Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease
DE3422249A1 (de) 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Wasserloesliches eisendextran und verfahren zu seiner herstellung
EP0166315B1 (de) 1984-06-19 1989-08-23 BASF Aktiengesellschaft Magensaftresistent überzogene zylindrische Pankreatin-Mikrotabletten
US5055288A (en) 1987-06-26 1991-10-08 Advanced Magnetics, Inc. Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides
US4827945A (en) 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US4970079A (en) 1989-06-05 1990-11-13 Purdue Research Foundation Method and composition of oxy-iron compounds for treatment of hyperphosphatemia
IL98744A0 (en) 1990-07-06 1992-07-15 Gen Hospital Corp Method of studying biological tissue using monocrystalline particles
SU1807606A1 (ru) * 1991-03-29 1995-08-09 Пермский политехнический институт Способ получения анионообменника на основе гидроксида титана
US5234697A (en) 1992-06-22 1993-08-10 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
DE69320120T2 (de) 1992-09-04 1999-04-08 Mitsubishi Chem Corp Verfahren zur Herstellung und Verwendung eines Anionen- austauscherharzes
DE4239442C2 (de) 1992-11-24 2001-09-13 Sebo Gmbh Verwendung eines mit polynuklearen Metalloxidhydroxiden modifizierten Adsorptionsmaterials zur selektiven Elimination von anorganischem Phosphat aus proteinhaltigen Flüssigkeiten
DE19547356A1 (de) 1995-12-19 1997-06-26 Vifor Int Ag Adsorbens für Phosphat aus wäßrigem Medium, dessen Herstellung und Verwendung
US5906978A (en) * 1996-08-14 1999-05-25 Hemocleanse, Inc. Method for iron delivery to a patient by transfer from dialysate
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
DE10128511A1 (de) 2001-06-13 2002-12-19 Sebo Gmbh Verwendung eines Phosphatadsorbers gegen Gefäßerkrankungen
US20050107253A1 (en) 2001-12-21 2005-05-19 Hiroyuki Sano Adsorbent for phosphoric acid
DE102004031181A1 (de) * 2004-06-28 2006-01-19 Vifor (International) Ag Phosphatadsorbens

Also Published As

Publication number Publication date
MA30993B1 (fr) 2009-12-01
NZ576672A (en) 2012-02-24
SI2319804T1 (sl) 2015-01-30
TWI465239B (zh) 2014-12-21
ECSP099410A (es) 2009-07-31
RU2447933C2 (ru) 2012-04-20
IL198548A0 (en) 2010-02-17
AR064301A1 (es) 2009-03-25
WO2008071747A1 (en) 2008-06-19
PT2319804E (pt) 2014-11-24
US8252310B2 (en) 2012-08-28
RU2009126614A (ru) 2011-01-20
HK1133248A1 (en) 2010-03-19
US20120126440A1 (en) 2012-05-24
US20080145410A1 (en) 2008-06-19
MY151047A (en) 2014-03-31
BRPI0720272A2 (pt) 2014-01-28
MX2009006307A (es) 2009-06-23
PE20081381A1 (es) 2008-11-12
NO20092632L (no) 2009-07-14
CA2671828A1 (en) 2008-06-19
CA2671828C (en) 2012-06-19
JP5456969B2 (ja) 2014-04-02
AU2007331482A1 (en) 2008-06-19
JP2008150375A (ja) 2008-07-03
TN2009000214A1 (en) 2010-10-18
NO342285B1 (no) 2018-04-30
TW200831115A (en) 2008-08-01
CL2007003606A1 (es) 2008-07-18
KR20090094820A (ko) 2009-09-08
AU2007331482B2 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
ES2526171T3 (es) Adsorbente de fosfato a base de hierro (III)-carbohidratos
US5399700A (en) Method for preparing enteric-coated oral drugs containing acid-unstable compounds
KR850000242A (ko) 작용 지속형 세파클로르 제제의 제조방법
JP2006514119A (ja) 溶解率が向上した難溶性薬剤の溶媒系
JP2009544617A5 (es)
KR20220101604A (ko) 제약학적 공융 염 제제
CN109562060A (zh) 混合粘膜粘着剂递送体系和其用途
CN104955801B (zh) 取代的二芳基磺酰胺及其用途
CN107922288A (zh) 芳基化合物的合成
FI117865B (fi) Lääkeainesuoloja
US20210163418A1 (en) Formulated and/or Co-Formulated Liposome Compositions Containing IDO Antagonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof
US20210260197A1 (en) Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof
CN110167548A (zh) 用于治疗胃肠息肉的组合物和方法
AU2014205324A1 (en) Vitamins C and K for treating polycystic diseases
CN114901275A (zh) 可用于治疗癌症的含有Toll样受体(“TLR”)激动剂前药的配制和/或共同配制的脂质体组合物及其方法
CN102327217B (zh) 一种头孢泊肟酯脂质体固体制剂
CN116507341A (zh) 用于治疗癌症的含有pd-1拮抗剂前药的调配和/或共同调配的脂质体组合物及其方法
CN107198683B (zh) 一种法呢基乙酸香叶醇酯药物组合物及其制备方法和用途
CN118286450A (en) Formulated and/or co-formulated liposomal compositions containing IDO antagonist prodrugs for treating cancer and methods thereof
CN116726185A (zh) 一种药物组合物及其制备方法和应用
CN101966166A (zh) 包含头孢克肟脂质体的胶囊剂及其制备方法
JP2024510613A (ja) がんの処置に有用なＡ２ａＲアンタゴニストプロドラッグを含有する製剤化および／または共製剤化されたリポソーム組成物ならびにその方法
JPS60199820A (ja) 新規化合物ｏｃ−１及びこれを有効成分とする制癌剤
JPS5843921A (ja) 制癌剤
CN101205205A (zh) 丙氨酸衍生物